FDA Accepts Biohaven’s Resubmitted Drug Application for Review
Biohaven said the FDA accepted its resubmitted New Drug Application for an experimental rare-disease drug.
By Mackenzie TatananniBiohaven stock was having its best day in three years after the Food and Drug Administration agreed to review a resubmitted application for the biotech's experimental rare-disease drug.Biohaven disclosed Thursday that U.S. regulators accepted a New Drug Application (NDA) resub…